Drug development doesn’t fail because data is missing. It fails because the data is everywhere at once — and nowhere useful when a decision needs to be made. That’s the problem Cheiron is building against, and on July 22 the Los Altos-based startup announced an $8 million seed round led by Menlo Ventures to do it.
Who’s backing it
The investor list is notable. Alongside Menlo Ventures, the round drew support from Moderna co-founder Robert Langer, former Pfizer Chief Medical Officer Freda Lewis-Hall, Chai Discovery CEO Josh Meier, and former Apple AI chief John Giannandrea. Menlo partner Venky Ganesan is joining the board. That’s a coalition of people who understand both the science and the operational weight of running drug programs at scale.
What Cheiron actually does
The core product is a Life Sciences Knowledge Graph, a structured intelligence layer that connects biomedical, clinical, regulatory, patent, and commercial knowledge into one model. The idea is that a drug program, with all its trials, filings, competitive data, assumptions, and decisions, should exist as a single connected system rather than a pile of documents and institutional memory.
Biopharma teams currently use Cheiron across clinical development, regulatory affairs, competitive intelligence, and program leadership. Boryung, one of South Korea’s top five pharma companies, is already a customer. CEO Jung Gyun Kim described it as moving from searching fragmented sources to actually understanding the full state of a program.
Why the timing matters
AI has been applied to drug discovery for years. But the execution layer, the part where programs live or stall, has had almost no infrastructure investment. Cheiron is targeting that gap. As Robert Langer put it: discovery gets the attention, but execution determines how fast medicines reach patients.
So the real question isn’t whether a knowledge graph for drug programs is useful. It’s whether Cheiron can become the default place where that program state lives. With tens of thousands of biopharma professionals already on the platform less than six months in, the early signal is real.
- Funding: $8M seed, led by Menlo Ventures
- Key backers: Robert Langer, Freda Lewis-Hall, Josh Meier, John Giannandrea
- Core technology: Life Sciences Knowledge Graph
- Use cases: Clinical development, regulatory affairs, competitive intelligence, program leadership
- Founded: 2024, headquartered in Los Altos, California
Learn more at cheiron.bio.